Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy

Elisa Bossi^{1

2}, Andrea Aroldi^{1

2}, Filippo A Brioschi^{1

2}, Carolina Steidl^{1

2}, Silvia Baretta¹, Rossella Renso¹, Luisa Verga¹, Diletta Fontana², Geeta G Sharma², Luca Mologni², Lara Mussolin^{3

4}, Rocco Piazza^{1

2}, Carlo Gambacorti-Passerini^{1

2}

Affiliations

¹ Hematology Division, San Gerardo Hospital, Monza, Italy.
² Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
³ Department Women's and Children's Health, Clinic of Pediatric Hemato-Oncology, University of Padua, Padua, Italy.
⁴ Institute of Pediatric Research, Fondazione Città della Speranza, Padova, Italy.

Free article

Clinical Trial

Elisa Bossi et al. Am J Hematol. 2020 Dec.

Free article

. 2020 Dec;95(12):E319-E321.

doi: 10.1002/ajh.25967. Epub 2020 Sep 3.

¹ Hematology Division, San Gerardo Hospital, Monza, Italy.
² Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
³ Department Women's and Children's Health, Clinic of Pediatric Hemato-Oncology, University of Padua, Padua, Italy.
⁴ Institute of Pediatric Research, Fondazione Città della Speranza, Padova, Italy.

No abstract available

References

1. Gritti G, Boschini C, Rossi A, et al. Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas. PLoS One. 2015;10(3):e0121822.
1. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190-2196.
1. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. N Engl J Med. 2011;364(8):775-776.
1. Gambacorti-Passerini C, Farina F, Stasia A, et al. Crizotinib in advanced, chemoresistant anaplastic lymphoma-kinase positive lymphoma patients. J Natl Cancer Inst. 2014;106(2):djt378.
1. Damm-Welk C, Mussolin L, Zimmermann M, et al. Early assessment of minimal residual disease identifies patients at very high relapse risk in NPM-ALK-positive anaplastic large-cell lymphoma. Blood. 2014;123(3):334-337.